Moderna Announces Data to be Presented at ESMO Congress 2025
-
EU defends Trump trade deal in face of backlash
-
England's Lionesses return to heroes' welcome after Euro 2025 glory
-
Hunger must never be 'weapon of war', UN chief tells Africa food summit
-
Heineken shares plummet as beer sales dry up
-
Trump slashes Russia ultimatum to '10 or 12 days'
-
Landslide kills four as rains lash northern China
-
Telegram's Durov questioned in France over alleged illegal content on app
-
Home from home: Trump showcases his resorts in golf diplomacy
-
EU accuses online giant Temu over sale of 'illegal' products
-
'No alternative' to two-state solution for Israel, Palestinians
-
US plan to destroy contraceptives sparks uproar
-
Turkey battles wildfires as heatwave grips Med
-
Dollar rises on EU-US trade deal but European stocks turn sour
-
Thai-Cambodia evacuees hail truce news with mixed emotions
-
Rivals laud 'phenomenally talented' 12-year-old swim sensation
-
Major Israeli rights groups brand Gaza campaign 'genocide'
-
EU defends Trump trade deal facing backlash
-
McIntosh wins again at swimming worlds as Yu, 12, just misses out
-
Trump says Gaza ceasefire 'possible' amid Starmer talks
-
McIntosh wins second Singapore gold, China prodigy Yu fourth
-
'Fragile' Walsh defies illness to win butterfly world gold
-
Hunger must never be 'weapon of war': UN chief
-
Brussels says EU-US deal 'better than trade war' with Trump
-
Three things we learned from Belgian F1 Grand Prix
-
Walsh defies illness in US camp to win butterfly world gold
-
Qin beats Olympic champ Martinenghi for 100m breaststroke world gold
-
Ireland's 'economic miracle' at risk from tariffs
-
Stock markets, dollar rise on EU-US trade deal
-
England's Lionesses head home to party after Euro glory
-
Philippine flooding centre stage at Marcos state of nation speech
-
Thailand and Cambodia agree truce after five days of fighting
-
Israeli settlers attack West Bank Christian village
-
Food arrives in Gaza after Israel pauses some fighting
-
Starmer to press Trump on Gaza, trade in Scotland talks
-
Jamie Overton added to England squad for fifth Test against India
-
China to offer childcare subsidies in bid to boost birth rate
-
Artists, scientists breathe life into prehistoric woman
-
Iconic French chef stakes reputation on vegan menu
-
CK Hutchison eyes 'major' Chinese investor for Panama ports deal
-
China hopes for 'reciprocity' at trade talks with US in Stockholm
-
England's remarkable Euro 2025 success a triumph for 'incredible' Wiegman
-
Four killed in landslide as heavy rain drenches northern China
-
Maduro's party sweeps Venezuela mayoral vote as opposition boycotts
-
Thailand and Cambodia begin truce talks as fighting drags on
-
Stock markets boosted after EU, US strike trade deal
-
Four killed as heavy rain, flooding soaks northern China
-
Heineken sees beer sales dip but keeps profit outlook
-
China's Pan puzzled after shock 200m free exit at swimming worlds
-
Honkytonk Kenya: Africa's home of country music
-
Head of China's Shaolin Temple removed over embezzlement claims
NYSE - LSE
| CMSC | -0.02% | 22.48 | $ | |
| RBGPF | 0% | 75 | $ | |
| RYCEF | 0.38% | 13.2 | $ | |
| BCC | 0.03% | 88.17 | $ | |
| RELX | -1.35% | 52.03 | $ | |
| SCS | 3.02% | 10.91 | $ | |
| VOD | -2.37% | 11.165 | $ | |
| NGG | -1.69% | 70.95 | $ | |
| GSK | -0.7% | 37.705 | $ | |
| RIO | -1.35% | 62.26 | $ | |
| SCU | 0% | 12.72 | $ | |
| BCE | -0.69% | 24.035 | $ | |
| JRI | -0.23% | 13.06 | $ | |
| CMSD | 0.17% | 22.93 | $ | |
| AZN | -0.69% | 72.16 | $ | |
| BTI | -0.72% | 51.875 | $ | |
| BP | 1.12% | 32.565 | $ |
Moderna Announces Data to be Presented at ESMO Congress 2025
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025 in Berlin, Germany. This includes a mini oral presentation on mRNA-4359, Moderna's investigational mRNA-based therapy designed to elicit T-cell immune responses against tumor and immunosuppressive cells, as well as two poster presentations on intismeran autogene (V940/mRNA-4157). Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
The details of the presentations are as follows:
Presentation #1515MO: Clinical Outcomes and PD-L1 Expression Analyses from a Trial of mRNA-4359 Plus Pembrolizumab in Checkpoint Inhibitor-Resistant/Refractory (CPI-R/R) Melanoma
Mini Oral Presentation: October 17, 2025, 2:00 - 3:30 PM CET
Location: Nuremberg Auditorium - Hall 5.2
Presenter: David J. Pinato
Presentation #3135eTiP: INTerpath-011: Phase 2 study of intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-Guérin (BCG) versus BCG alone for high-risk (HR) non-muscle-invasive bladder cancer (NMIBC)
Presenter: Petros Grivas
Presentation #1684TiP: Intismeran autogene (V940/mRNA-4157) + pembrolizumab versus pembrolizumab alone as first-line therapy for advanced melanoma: the phase 2 INTerpath-012 study
Presenter: Paolo A. Ascierto
Moderna Investor Event
Moderna will host an analyst event while at ESMO. Details of the event to follow.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
[email protected]
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
P.Martin--AMWN
